Table 2.
Demographics and clinical characteristics for patients, categorized by training and test sets.
| Characteristics | All patients (n = 153) | Training set (n = 77) | Test set (n = 76) | p-Value | |
|---|---|---|---|---|---|
| Sex | Male | 78 (52%) | 43 (56%) | 35 (46%) | 0.26 |
| Female | 75 (48%) | 34 (44%) | 41 (54%) | ||
| Age | Median (IQR) [95% CI] |
66 (13) [64.97–68.16] |
6712.5) [64.00–68.67] |
66 (14) [64.62–68.98] |
0.89 |
| Race | White | 98 (82%) | 48 (62%) | 50 (66%) | 0.73 |
| Black | 55 (18%) | 29 (38%) | 26 (34%) | ||
| Smoking | Never | 6 (4%) | 3 (4%) | 3 (4%) | 1.00 |
| Former/current | 147 (96%) | 74 (96%) | 73 (96%) | ||
| Stage | Limited stage | 21 (14%) | 10 (13%) | 11 (14%) | 0.81 |
| Extensive stage | 132 (86%) | 67 (87%) | 65 (86%) | ||
| Chemotherapy Agents | Carboplatin | 64 (42%) | 30 (39%) | 34 (45%) | 0.51 |
| Cisplatin | 89 (58%) | 47 (61%) | 42 (55%) | ||
| Median OS | Months (IQR) [95% CI] |
9.37 (12.73) [11.63–15.77] |
8.27 (12.55) [10.10–16.40] |
10.18 (12.48) [11.46–16.85] |
0.12 |
| Median PFS | Months (IQR) [95% CI] |
8.35 (11.8) [11.2–16.84] |
7.57 (12.2) [9.68–17.36] |
9.23 (11.9) [10.37–18.68] |
0.19 |